Arrowhead Research | ARWR - Umlaufvermögen

Aktienkurs
72.87
Täglich Wechseln
2.34 3.32%
Monatlich
16.22%
Jährlich
419.02%
Q2 Prognose
72.33




Umlaufvermögen Veränderung Datum
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.17B 223.75M 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Ligand Pharmaceuticals USD 832.27M 78.35M 2025-12
Merck USD 43.52B 4.04B 2025-12
Moderna USD 6.54B 54M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
TG Therapeutics USD 630.76M 31M 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12
Xencor USD 599.82M 81.38M 2025-12